From Design to Dispense: Pharma’s Supply Chain Enters the AI Orchestration Era

The winners in pharma supply chain will not just digitize individual workflows; they will coordinate regulated physical execution across systems, partners and handoffs.

For years, pharma operators have discussed “Pharma 4.0,” the “plant of the future,” and “smart manufacturing.” But at a time when operators face growing challenges posed by advanced therapeutics, new compliance burdens and global network coordination, the promise of a unified supply chain can seem further away than ever.

While the industry is unlikely to bridge this growing gap if we continue to rely on compartmentalized systems, data and partner networks, the adoption of AI has the potential to connect the systems that have historically only operated in parallel. AI can orchestrate the supply chain from the shop floor to pharmacy dispense with cloud-delivered workflows, governed data layers, edge connectivity and workflow-specific agents.

In this GrowthBit, we’ll look at how the physical pharma supply chain is changing, why specialty therapeutics are accelerating that change, and the transformative impact AI orchestration is already having on the entire pharma supply chain journey.

The next generation of vendors is not just digitizing the status quo. It is moving from static records and disconnected portals to orchestrated execution from initial design all the way through to dispense. Anshul Mangal, LLR Advisor & President, PerkinElmer OneSource

Specialty therapies drive increased complexity

The physical pharma supply chain is becoming harder to operate as advanced therapies and personalized medicines take greater share. In 2023, the FDA approved 55 novel drugs, the highest annual total since 2018,¹ and biologics are expected to represent roughly 55% of innovative drug sales.² These specialty therapies tend to be lower-volume, higher-cost, more sensitive and more dependent on precise handling across production, packaging, storage, distribution and dispensing, intensifying the need for more specialized manufacturing and distribution workflows.

The shift away from traditional small molecules is changing what the physical supply chain is required to support. For operators, the practical implication is not only more variation in modality greater need for cold storage; there are now more exceptions, handoffs and data that need to be understood in context.

These therapies often require cold-chain logistics, specialized packaging, real-time monitoring and modality-specific coordination. In cell and gene therapy, the operating model becomes even more specialized because chain of custody, chain of identity, timing and storage conditions are critical to product integrity.³ As products become more tailored to individual patients, the supply chain cannot be managed with traditional static snapshots.

Compliance burdens are expanding

Traceability requirements are raising the bar for documentation, serialization, custody evidence and auditability across the supply chain. DSCSA is a clear example; phased enforcement deadlines in 2025 placed pressure on manufacturers, wholesale distributors and dispensers to support electronic, package-level traceability.⁴

Track-and-trace has expanded beyond visibility alone. Teams increasingly need interoperable data exchange, package-level records, condition monitoring and exception handling embedded into daily operations. In the next generation of supply chain software, compliance becomes an operating layer. Evidence is captured as work happens, exceptions are routed instantaneously and AI helps prioritize what requires review without removing human accountability.

At the same time, regulatory thinking is increasingly focused on modernizing compliance rather than forcing modern software into legacy validation models. Risk-based software assurance approaches are gaining relevance as regulated organizations adopt cloud software, continuous updates and AI-enabled workflows while preserving objective evidence and human accountability.⁵

The ‘plant of the future’ is not confined to the four walls of a facility.

Global networks require tight coordination

Onshoring remains a tailwind for domestic pharma manufacturing, but the underlying supply chain is still highly globalized. The U.S. continues to rely on manufacturing facilities abroad for most active pharmaceutical ingredients, and FDA data found that only about 28% of API facilities supplying the U.S. market were located domestically.⁶

This means sponsors still need to coordinate sourcing, quality, documentation, customs, handoffs and risk management across a growing number of nodes and jurisdictions. The “plant of the future” is not confined to the four walls of a facility. It is a networked operating model that connects sourcing, production, release and distribution as products move through partner ecosystems.

The bottleneck is no longer only manufacturing capacity or logistics execution, but coordinated, compliant decision-making across the network.

Software solutions are increasingly critical

The pressures facing the pharma supply chain share a common operating challenge: the data needed to make decisions is distributed across systems, partners, documents and physical handoffs. As a result, the bottleneck is no longer only manufacturing capacity or logistics execution, but coordinated, compliant decision-making across the network. This makes validated, interoperable software increasingly critical across the supply chain. This includes:

• MES platforms for production execution and electronic batch records
• LIMS platforms for lab testing, sample management, release testing and quality operations
• QMS, digital validation and validation management tools for quality, documentation and audit readiness
• EAM / ALM systems for regulated equipment, calibration, maintenance and asset history
• PLM platforms for product knowledge, tech transfer, CMC change control and lifecycle governance
• Label and artwork management; manufacturing analytics; serialization and chain-of-custody tracking; cold-chain telemetry; and modality-specific orchestration tools for CGT and other high-complexity workflows

Operators are not asking for another dashboard; they are asking for systems to explain what is happening, what is at risk and what to do next…

The largest opportunity is the AI-enabled unified operations layer

AI is becoming increasingly useful within the traditional manufacturing workflows listed above, but adoption remains uneven. While some organizations are digitizing core workflows and building governed data foundations, others are beginning to experiment with AI-enabled coordination layers including batch record review, predictive maintenance, real-time monitoring, quality assurance, earlier deviation detection, faster review cycles and better exception handling.

But the sharper AI-enabled opportunity is to connect these categories through governed data and workflow orchestration rather than forcing operators to reconcile disconnected point solutions after the fact. This is where the market is heading, even if the transition happens in stages and at different rates across manufacturers, CDMOs and software vendors.

Individual workflows still matter, but the opportunity is shifting toward software that can serve as a governed system of action across regulated operations. Operators are not asking for another dashboard; they are asking for systems that can explain what is happening, what is at risk and what to do next while preserving the audit trail behind every action. In such highly regulated environments, the point is not just efficiency through automation. It is faster, better-informed, human-in-the-loop decision-making.

Here’s the bottom line.

For years, operators have heard promises about the plant and supply chain of the future. Despite the challenges posed by specialty therapies, compliance and globalization, cloud-native platforms, governed data layers and AI-enabled orchestration are making good on that promise. Companies positioned to create audit-ready visibility and tighter execution from manufacturing through dispense are better equipped to support sponsors, partners and patients with fewer manual handoffs and preventable exceptions. The winners will not just digitize individual workflows; they will coordinate regulated physical execution across systems, partners and handoffs.

Learn more about the LLR team, relevant investment experience and our focus on the Pharma Physical Supply Chain sector.